Table 2 Patient disposition at end of study.

From: Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Variable, n (%)

ASC + NIL, all patients

(n  =  26)

ASC + IMA, all patients

(n  =  25)

ASC + DAS, all patients

(n = 32)

Patients enrolled

 Treated

26 (100.0)

25 (100.0)

32 (100.0)

Reason for discontinuation of study treatment

 Adverse event

3 (11.5)

4 (16.0)

3 (9.4)

 Physician decision prior to end of study

8 (30.8)

5 (20.0)

7 (21.9)

      Lack of efficacy

7 (26.9)

5 (20.0)

3 (9.4)

      Other reasonsa

1 (3.8)

0 (0)

4 (12.5)

 Progressive disease

1 (3.8)

2 (8.0)

1 (3.1)

 Patient/guardian decision

2 (7.7)

1 (4.0)

0 (0)

 Death

0 (0)

1 (4.0)

0 (0)

 Pregnancy

0 (0)

1 (4.0)

0 (0)

 Lost to follow-up

0 (0)

1 (4.0)

0 (0)

Discontinuation of ATP-competitive TKI

10

6

12

Reason for discontinuation of ATP-competitive TKI, n

 Adverse event

6

2

10

 Physician decision

4

1

2

 Patient decision

0

2

0

 Progressive disease

0

1

0

Completed study and continued in PTAb

12 (46.2)

10 (40.0)

21 (65.6)

  1. ASC asciminib, ATP adenosine triphosphate, DAS dasatinib, IMA imatinib, NIL nilotinib, PTA post-trial access, TKI tyrosine kinase inhibitor.
  2. aIncludes in the ASC + NIL arm, intolerance (n = 1); in the ASC + DAS arm, intolerance safety precaution, planned pregnancy, unable to comply with study procedures, and not indicated to continue in the study (n = 1 each). bStudy allowed continuation on treatment based on physician’s assessment of benefit.
Back to article page